Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy
Cet article passe en revue les biomarqueurs génomiques pour prédire la réponse ou la résistance aux inhibiteurs de point de contrôle immunitaire
Immune checkpoint blockade (ICB) has transformed cancer care over the last ten years, inducing durable tumor responses that translate into long-term survival. This success has allowed many patients across a variety of tumor typesto live well with cancer. However, not all tumor types have the same capacity to respond to ICB, and not all patients with a given type of tumor known to be responsive to ICB will benefit from it. In this issue of the Journal, Fountzilas and colleagues’review provides an overview of currently approved and emerging genomic biomarkers for ICB that may predict response or resistance to therapy.
Journal of the National Cancer Institute , éditorial en libre accès, 2020